Insight Molecular Diagnostics Inc. (LON:0KCC)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 105.89M +93.8% |
| Revenue (ttm) | 1.26M -60.8% |
| Net Income | -37.20M |
| EPS | -1.10 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 161 |
| Open | 4.325 |
| Previous Close | 4.360 |
| Day's Range | 4.260 - 4.490 |
| 52-Week Range | 2.425 - 7.770 |
| Beta | 1.82 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About LON:0KCC
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test ... [Read more]
Financial Performance
In 2025, LON:0KCC's revenue was $4.06 million, an increase of 115.58% compared to the previous year's $1.88 million. Losses were -$50.22 million, -17.57% less than in 2024.
Financial numbers in USD Financial StatementsNews
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, Au...
Insight Molecular Diagnostics Earnings Call Transcript: Q2 2026
FDA review for GraftAssureDx is progressing, with expanded Medicare reimbursement and strong clinical data supporting commercial prospects. Adjusted EBITDA loss narrowed to $7.8M in Q2, and cash burn is expected to decrease as the company prepares for commercialization and market expansion.
Insight Molecular Diagnostics Shareholder letter: Q2 2026
Insight Molecular Diagnostics has published a letter to shareholders covering Q2 2026, which was released on August 10, 2026.
Insight Molecular Diagnostics Earnings release: Q2 2026
Insight Molecular Diagnostics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Insight Molecular Diagnostics Quarterly report: Q2 2026
Insight Molecular Diagnostics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c)
Reports Q2 revenue $239,000, consensus $437,500. The company said, “Our Q2 2026 outgoing cash flow from operations (net cash used in operating activities) of $9.3 million, combined with capital expend...
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the mark...
Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay
Insight Molecular Diagnostics (IMDX) highlighted the publication of a study in The Lancet Regional Health – Europe, part of the Lancet Group, demonstrating the potential role of donor-derived cell-fre...
iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication
Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection Serial monitoring of patients through donor-derived cell-free...
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor...
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of mole...
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-
Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry
NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, the...
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced an online published article in the American Journal of Transplantation a...
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced it will be highlighting its GraftAssure™ technology at the upcoming Amer...
Insight Molecular Diagnostics Earnings Call Transcript: Q1 2026
GraftAssureDx FDA review is progressing, with first U.S. orders expected later this year. Q2 revenue is projected at $250,000 and cash burn to peak above $9 million before declining. International traction is building, and long-term gross margins are targeted at 70% or higher.
Insight Molecular Diagnostics Earnings release: Q1 2026
Insight Molecular Diagnostics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Insight Molecular Diagnostics Shareholder letter: Q1 2026
Insight Molecular Diagnostics has published a letter to shareholders covering Q1 2026, which was released on May 13, 2026.
Insight Molecular Diagnostics Quarterly report: Q1 2026
Insight Molecular Diagnostics has published its Q1 2026 quarterly earnings report on May 13, 2026.
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first t...
Insight Molecular Diagnostics Slides: Investor presentation
Insight Molecular Diagnostics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
iMDx to Release First Quarter 2026 Results on May 13, 2026
NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market...
Insight Molecular Diagnostics Proxy statement: Proxy filing
Insight Molecular Diagnostics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Insight Molecular Diagnostics Proxy statement: Proxy filing
Insight Molecular Diagnostics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Insight Molecular Diagnostics Transcript: 25th Annual Needham Virtual Healthcare Conference
Insight Molecular Diagnostics is advancing GraftAssure, a decentralized transplant rejection test using droplet digital PCR, with strong clinical data and a dual quantification approach. The company targets rapid U.S. and EU expansion, robust margins, and is positioned to benefit from new anti-rejection therapies.